After finishing at $1.47 in the prior trading day, Petros Pharmaceuticals Inc (NASDAQ: PTPI) closed at $1.45, down -1.36%. In other words, the price has decreased by -$0.0200 from its previous closing price. On the day, 5110326 shares were traded.
Ratios:
Our goal is to gain a better understanding of PTPI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 3.02. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 1.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTPI now has a Market Capitalization of 3.24M and an Enterprise Value of -6.05M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46 while its Price-to-Book (P/B) ratio in mrq is 0.44. Its current Enterprise Value per Revenue stands at -0.87 whereas that against EBITDA is 0.69.
Stock Price History:
The Beta on a monthly basis for PTPI is 2.28, which has changed by -0.68% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, PTPI has reached a high of $9.54, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 1.3975, while the 200-Day Moving Average is calculated to be 1.9144.
Shares Statistics:
The stock has traded on average 949.75K shares per day over the past 3-months and 1.06M shares per day over the last 10 days, according to various share statistics. A total of 2.08M shares are outstanding, with a floating share count of 1.31M. Insiders hold about 40.34% of the company’s shares, while institutions hold 5.30% stake in the company. Shares short for PTPI as of Feb 29, 2024 were 317.19k with a Short Ratio of 0.33, compared to 242.4k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.41% and a Short% of Float of 23.07%.
Earnings Estimates
Its stock is currently analyzed by 1 different market analysts. The consensus estimate for the next quarter is -$1.19, with high estimates of -$1.19 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$5.15 and -$5.15 for the fiscal current year, implying an average EPS of -$5.15. EPS for the following year is -$5.01, with 1 analysts recommending between -$5.01 and -$5.01.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $6M in the next fiscal year. The high estimate is $6M and the low estimate is $6M. The average revenue growth estimate for next year is down -22.10% from the average revenue estimate for this year.
